» Articles » PMID: 23715501

MiR-192, MiR-194 and MiR-215: a Convergent MicroRNA Network Suppressing Tumor Progression in Renal Cell Carcinoma

Overview
Journal Carcinogenesis
Specialty Oncology
Date 2013 May 30
PMID 23715501
Citations 89
Authors
Affiliations
Soon will be listed here.
Abstract

MicroRNAs (miRNAs) play a crucial role in tumor progression and metastasis. We, and others, recently identified a number of miRNAs that are dysregulated in metastatic renal cell carcinoma compared with primary renal cell carcinoma. Here, we investigated three miRNAs that are significantly downregulated in metastatic tumors: miR-192, miR-194 and miR-215. Gain-of-function analyses showed that restoration of their expression decreases cell migration and invasion in renal cell carcinoma cell line models, whereas knockdown of these miRNAs resulted in enhancing cellular migration and invasion abilities. We identified three targets of these miRNAs with potential role in tumor aggressiveness: murine double minute 2, thymidylate synthase, and Smad Interacting protein 1/zinc finger E-box binding homeobox 2. We observed a convergent effect (the same molecule can be targeted by all three miRNAs) and a divergent effect (the same miRNA can control multiple targets) for these miRNAs. We experimentally validated these miRNA-target interactions using three independent approaches. First, we observed that miRNA overexpression significantly reduces the mRNA and protein levels of their targets. In the second, we observed significant reduction of the luciferase signal of a vector containing the 3'UTR of the target upon miRNA overexpression. Finally, we show the presence of inverse correlation between miRNA changes and the expression levels of their targets in patient specimens. We also examined the prognostic significance of miR-215 in renal cell carcinoma. Lower expression of miR-215 is associated with significantly reduced disease-free survival time. These findings were validated on an independent data set from The Cancer Genome Atlas. These results can pave the way to the clinical use of miRNAs as prognostic markers and therapeutic targets.

Citing Articles

Molecular mechanisms of miR-192 in cancer: a biomarker and therapeutic target.

Yang Y, Razak S, Ismail I, Ma Y, Yunus M Cancer Cell Int. 2025; 25(1):94.

PMID: 40087755 DOI: 10.1186/s12935-025-03666-5.


wMKL: multi-omics data integration enables novel cancer subtype identification via weight-boosted multi-kernel learning.

Cao H, Jia C, Li Z, Yang H, Fang R, Zhang Y Br J Cancer. 2024; 130(6):1001-1012.

PMID: 38278975 PMC: 10951206. DOI: 10.1038/s41416-024-02587-w.


The Role of microRNAs in Gene Expression and Signaling Response of Tumor Cells to an Acidic Environment.

Riemann A, Rauschner M, Reime S, Thews O Int J Mol Sci. 2023; 24(23).

PMID: 38069241 PMC: 10707721. DOI: 10.3390/ijms242316919.


Identification of hub genes and microRNAs with prognostic values in esophageal cancer by integrated analysis.

Mokhlesi A, Sharifi Z, Berimipour A, Taleahmad S, Talkhabi M Noncoding RNA Res. 2023; 8(3):459-470.

PMID: 37416747 PMC: 10319852. DOI: 10.1016/j.ncrna.2023.05.009.


Improving the prediction for the response to radiotherapy of clinical tumor samples by using combinatorial model of MicroRNA expression.

Tang C, Qi J, Wu Y, Luo L, Wang Y, Wu Y Front Genet. 2022; 13:1069112.

PMID: 36482894 PMC: 9723130. DOI: 10.3389/fgene.2022.1069112.